dr reddy's glp-1 drugs portfolio 2025 With the launch of Obeda®, India's first DCGI-approved semaglutide injection for Type 2 Diabetes, we are excited to support diabetes care in India with high-quality, accessible and affordable treatment. In a head-to-head title Today we launch, Obeda®,
Description
Reconstr Surg
In the SURMOUNT-1 clinical trial, patients taking the highest dose (15 mg) of tirzepatide lost about 21% of their body weight over 72 weeks
JMIR Res Protoc 6(9):e181
How neural mediation of anticipatory and compensatory insulin release helps us tolerate food
The drug, manufactured by Novo Nordisk, is approved for the treatment of Type 2 diabetes but has been increasingly used for weight loss
Sources: Hedgman, A
